How sham patents are hurting the pharma industry
The FTC is cracking down on pharma companies filing sham patents in the Orange Book to delay generics competition.
The FTC is cracking down on pharma companies filing sham patents in the Orange Book to delay generics competition.
Rakovina has expanded research collaborations with Pharma Inventor and the University of British Columbia to identify novel drug candidates.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Biotechs must prioritise ethics to deter GenAI “bad actors”
AstraZeneca to withdraw Covid-19 vaccine globally
GSK, Lundbeck, ROVI: Three Journeys of Unified Pharma Events Management
NIH team develops AI tool to predict cancer drug response